×

Sarepta soars as FDA delays review of key drug

12:15 PM ET Wed, 25 May 2016

CNBC's Dominic Chu reports on Sarepta Therapeutics and its Duchenne muscular dystrophy drug trial. The "FMHR" traders weigh in on the trade.